Read more
4:36 PM ยท 27 January 2025

Massive sell-off in Allakos shares following disappointing clinical trial results for AK006 ๐Ÿ“‰

Allakos (ALLK.US) is down more than 77% today after releasing disappointing results from clinical trials of its drug AK006. The drug was intended to treat Chronic Spontaneous Urticaria (CSU), but the phase 1 trial results did not demonstrate sufficient therapeutic activity. As a result, the company has decided to abandon the project, which was one of its leading programs. Following the discontinuation of the project, the company announced it will lay off 75% of its workforce and will begin a review of available strategies to find a new alternative for its future operations.

 

Source: xStation

17 April 2026, 2:39 PM

Rallies in European airline valuations

17 April 2026, 2:34 PM

US OPEN: The Strait of Hormuz is fully open ๐Ÿ’ฅEuphoria in the markets ๐Ÿš€

17 April 2026, 11:09 AM

Market wrap: Peace rumours and disapointing earnings

17 April 2026, 6:55 AM

Morning Wrap: Trump Announces Ceasefire Between Israel and Lebanon

The financial instruments we offer, especially CFDs, can be highly risky. Fractional Shares (FS) is an acquired from XTB fiduciary right to fractional parts of stocks and ETFs. FS are not a separate financial instrument. The limited corporate rights are associated with FS.
This page was not created for investors residing in Brazil. This brokerage is not authorized by the Comissรฃo de Valores Mobiliรกrios (CVM) or the Brazilian Central Bank (BCB). The content of this page should not be characterized as an investment offer in Brazil or for investors residing in that country.
Losses can exceed deposits